204.92
-0.72 (-0.35%)
| Previous Close | 205.64 |
| Open | 205.90 |
| Volume | 275,927 |
| Avg. Volume (3M) | 231,008 |
| Market Cap | 4,086,338,304 |
| Price / Earnings (TTM) | 33.43 |
| Price / Earnings (Forward) | 24.10 |
| Price / Sales | 15.51 |
| Price / Book | 4.02 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -73.07% |
| Operating Margin (TTM) | -80.87% |
| Diluted EPS (TTM) | -7.29 |
| Quarterly Revenue Growth (YOY) | 46.30% |
| Total Debt/Equity (MRQ) | 0.56% |
| Current Ratio (MRQ) | 5.27 |
| Operating Cash Flow (TTM) | 52.87 M |
| Levered Free Cash Flow (TTM) | 63.35 M |
| Return on Assets (TTM) | -1.14% |
| Return on Equity (TTM) | -16.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Ligand Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.30 |
|
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 100.00% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Chicago Capital, Llc | 31 Dec 2025 | 561,423 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 277.00 (Oppenheimer, 35.18%) | Buy |
| Median | 244.00 (19.07%) | |
| Low | 239.00 (HC Wainwright & Co., 16.63%) | Buy |
| Average | 253.33 (23.62%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 202.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 11 Mar 2026 | 244.00 (19.07%) | Buy | 221.24 |
| Oppenheimer | 27 Feb 2026 | 277.00 (35.17%) | Buy | 198.31 |
| HC Wainwright & Co. | 24 Feb 2026 | 239.00 (16.63%) | Buy | 189.00 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KOZARICH JOHN W | - | 199.62 | -467 | -93,223 |
| REARDON ANDREW | - | 199.62 | -5,000 | -998,100 |
| Aggregate Net Quantity | -5,467 | |||
| Aggregate Net Value ($) | -1,091,323 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 199.62 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| REARDON ANDREW | Officer | 01 Apr 2026 | Automatic sell (-) | 5,000 | 199.62 | 998,100 |
| REARDON ANDREW | Officer | 01 Apr 2026 | Option execute | 5,000 | - | - |
| KOZARICH JOHN W | Director | 01 Apr 2026 | Automatic sell (-) | 467 | 199.62 | 93,223 |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |